PNPLA7

Across TCGA pan-cancer cohorts, PNPLA7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PNPLA7 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PNPLA7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PNPLA7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where PNPLA7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.881	0.224	.007	10	view →
LSCC	DFS	Tertile	II,III,IV	0.256	0.892	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PNPLA7–LUAD (DFS)

Open the LUAD breakdown →